Latest news with #Level
5 days ago
- Business
OTC Markets Group Welcomes Badger Infrastructure Solutions Ltd. to OTCQX
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Badger Infrastructure Solutions Ltd. (TSX: BDGI; OTCQX: BDGIF), North America's largest provider of non-destructive excavating and related services, has qualified to trade on the OTCQX® Best Market. Badger Infrastructure Solutions Ltd. upgraded to OTCQX from the Pink® market. Badger Infrastructure Solutions Ltd. begins trading today on OTCQX under the symbol 'BDGIF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws. "We are excited to be added to the OTCQX® Best Market, which provides the opportunity to broaden our market access, enhance liquidity, and strengthen our U.S. investor presence. This move enhances our visibility within the U.S. investment community and provides a convenient way for investors to trade our shares in their own currency and local market. It positions us to expand our investor base as we continue to build sustainable, scalable growth while delivering exceptional service and value to our customers and stakeholders," said Rob Blackadar, Badger Infrastructure's President & CEO. About Badger Infrastructure Solutions Infrastructure Solutions Ltd. is North America's largest provider of non-destructive excavating and related services. Badger works for contractors and facility owners in a broad range of infrastructure industries and in general commercial construction. Badger's customers typically operate near high concentrations of underground power, communication, water, gas and sewer lines, where safety and economic risks are high and where non-destructive excavation provides a safe alternative for certain customer excavation requirements. The Company's key technology is the Badger HydrovacTM, which uses a pressurized water stream to liquify the soil cover, which is then removed with a powerful vacuum system and deposited into a storage tank. Badger is unique in the non-destructive excavation industry because it designs and manufactures all of its hydrovac units at its plant in Red Deer, AB, which has an annual production capacity of more than 350 hydrovac units. To complement the Badger Hydrovac, the Company has a select number of specialty units, including combo trucks, sewer and flusher units, and Air Vacs. The Company is headquartered in Calgary, AB, has a U.S. administrative office and training centre in Brownsburg, IN, a suburb of Indianapolis, IN, and services customers from approximately 140 field locations across both Canada and the United Sates. About OTC Markets Group Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS™ are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit Subscribe to the OTC Markets RSS Feed Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@ in to access your portfolio
CNET
21-05-2025
- Business
- CNET
Knock $145 Off Your Smart Home Upgrade With This Level Lock Plus Smart Lock Deal
The humble smart lock is often overlooked when people are setting up their new smart home, but that's a mistake. They can improve security and make it more convenient when you enter and leave your home -- and they're downright cool, too. Unfortunately, they can be expensive. Thankfully, Best Buy has slashed the price of a Level Lock Plus with a keypad all the way down to just $284. That's a massive $145 of savings from its usual asking price of $429, so it's quite a discount. The catch? You'll need to act fast. This one-day deal ends tonight, so make sure to order your new Level Lock Plus smart lock before it's too late. Level's locks aim for quality more than affordability, with an ANSI rating of 156.40 and temperature resistance to provide maximum durability. It's rated to last for 136 years with average use. The brand also offers a variety of finishes and additional lever designs to find your door's best look. But those high-end features can be costly, so we're glad to see this Level Lock -- one of our favorite models -- drop to less than $300. If you're looking for more ways to smarten up your home, check out the top deals on smart home gadgets happening right now. Hey, did you know? CNET Deals texts are free, easy and save you money. The most attractive thing about the Level's Lock Plus? It doesn't look like a smart lock. There's no awkward-shaped retrofit or backside bulk holding a Wi-Fi connection. Instead, it looks exactly like a normal mortal deadbolt with a compact, even minimalist design that no one would guess hides smart tech along with a well-concealed, replaceable CR2 battery. This model does include a keypad, though, which you can install anywhere within 30 feet of your lock. That gives you plenty of leeway if you don't want a keypad to take away from your entryway's aesthetic. In addition to Alexa, Ring, Apple Home and Google Home support, you can manage locking via the Level app or just swipe your phone close or use the keypad to unlock at will. Plus, you can create passes for others or even buy physical NFC passes for people to use, so you still have plenty of options. You can also create and manage Apple Home Keys, another kind of digital pass that's particularly easy to use with an Apple Watch or iPhone. On top of all that, a physical key will still work. This particular kit includes the Level Lock Plus, the Connect Wi-Fi bridge, a keypad, a CR2 battery and two keys. Read more: Best Smart Home Gifts for Anyone For more, you can also see the latest updates to our complete list of home security systems or peruse our list of the best smart locks so you can have all of the information you need to make the right purchase for you. Why this deal matters There are many reasons to upgrade to a smart lock, and this one-day deal knocks $145 off one of our favorite options out there. It's very unlikely that the price will drop any lower any time soon, so we recommend picking this lock up today if you were already considering upgrading to a smart lock and it falls within your budget -- especially considering tariffs are causing prices to rise on many goods, including electronics.
CBS News
20-05-2025
- General
- CBS News
Man forced to live in tent after losing Altadena home in Eaton Fire gets help from community
A community steps up when a man is forced to live in a tent after the Eaton Fire A community steps up when a man is forced to live in a tent after the Eaton Fire A community steps up when a man is forced to live in a tent after the Eaton Fire An elderly man who lost his home in the Eaton Fire ended up living in a tent on his burned-out property, and his community is making sure he doesn't fall through the cracks. It was a modest room, but for Gary Van Ostrand, it was his home. "What's left is hardly recognizable," Van Ostrand said, looking at the rubble left of his home. After the Eaton Fire destroyed his Altadena home, the 73-year-old lived in the shelter at the Pasadena Convention Center. But after six weeks, he was given a gift card and a tub of his belongings. "I was told I had to go," he said. With nowhere to go, he bought a tent and set it up in what used to be his backyard. "There were coyotes circling around the day. The hungry coyotes, they were displaced like I was," he said. For two weeks, he was living atop the ashes of his old home, until a passerby posted about his situation. "This is really sad that this is how he ended up," said Ash Level, a community organizer. Level works with Altadena Rising, a group of volunteers that connects fire victims to resources. She rushed over to Van Ostrand and they immediately connected through their love of oldies. She said Van Ostrand's case is one of the most challenging she's seen. He's low-income, elderly, disabled, has no family, and struggles with applying for assistance. "To be honest, I'm completely inept when it comes to doing digital things," Van Ostrand said. Level and her team immediately took Van Ostrand to the doctor, helped him with his FEMA paperwork, and found him a hotel for another few weeks. But she said what he really needs is a long-term senior living community. "Help us find Gary a place with light and art, other elders that want to have fun," she said. Despite losing everything, the 73-year-old said he still has a dream to start something new, something he loves to do. Something that'll help out seniors just like him. Van Ostrand calls it "Gary-oke" it's a group singing activity for the elderly, that he hopes will help restore memory. "I can remember lyrics to songs I didn't even know that I remember," Van Ostrand said. "If that's true, that's a memory exercise that might help me remember what I had for breakfast." It's an idea Level supports 100%, and she hopes others feel the same.
Scottish Sun
09-05-2025
- Business
- Scottish Sun
British Airways spends £17billion on jets after Trump teased Boeing would get a bumper order under US-UK trade deal
BRITISH AIRWAYS' owner is spending £17billion on new jets — a day after Donald Trump teased Boeing would get a bumper British order under the US-UK trade deal. The request for 32 Boeing 787-10 aircraft for BA was announced yesterday by International Consolidated Airlines Group. 1 British Airways' owner is spending £17billion on new jets Credit: Getty It has also made a separate order with Europe's Airbus for 21 A330-900neo planes for its Aer Lingus, Iberia and Level carriers. It came just a day after US Trade Secretary Howard Lutnick said the UK would be buying '$10billion (£7billion) worth of Boeing planes' alongside its trade deal. IAG insiders yesterday said the order had been in the works for many months, rather than deliberately coordinated alongside the US-UK agreement. The aircraft are expected to arrive between 2028 and 2033 but mark IAG's first order for jets since the pandemic upended the travel industry. It is also the biggest deal Boeing has struck since a string of safety scandals — including a door peg blowing off midflight — caused significant delays and supply chain issues. IAG separately posted a 9.6 per cent rise in revenues during the first quarter to £7billion and swung back into the black with £176million of profits. Boss Luis Gallego said it 'marks a milestone in our strategy and transformation programme'. Shares rose 2 per cent yesterday to 296.1p. Moment Keir Starmer & Donald Trump seal UK-US trade deal in historic phone call POWER GAFFE TEN energy firms including Octopus, OVO and EDF have been ordered to pay back £7million to customers after overcharging them. Ofgem said 34,000 customers who had more than one electricity meter would receive compensation. Octopus, the UK's biggest supplier, paid out £2.64million in refunds and made a £546,278 goodwill payment. TRAVIS PERKIER BUILDING materials group Travis Perkins has poached Gavin Slark to fill its vacant CEO position from rival construction company SIG. Ex-boss Peter Redfern quit midway through a turnaround plan after just six months due to ill health. Mr Slark will take over in 2026 but the news lifted shares in Travis Perkins by as much as 6 per cent.
06-05-2025
- Business
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen's Chief Executive Officer (CEO), David Loew. 'We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura's involvement in major transformation projects across leading life science companies in different fronts – from post-merger integrations, commercial model designs and corporate transformations. She brings a rare combination of strategic vision, analytical rigor and ability to execute across different areas within the healthcare space,' said David Loew, CEO. Laura joins Ipsen from the Boston Consulting Group (BCG) where she was Partner, consulting across portfolio strategy, M&A, Go-to-Market, and operating model transformation projects. Over her 12-year tenure at BCG, Laura became a trusted partner for many pharmaceutical companies, having consulted with organizations ranging from small biotech firms to global pharma and MedTech companies. She has been exposed to a diversity of market dynamics, strategic contexts and corporate cultures proving a strong ability to navigate complex, high-stakes transformations across geographies and business models over her 20 year career in the broader healthcare industry. 'I am very excited to join Ipsen at this moment of the Group's transformation journey. Having had the opportunity to collaborate with the company in the past years, I am truly excited to jointly define and drive the next chapter of Ipsen's strategy,' said Laura Réveillon. Laura will succeed Catherine Abi Habib, EVP Strategy & Transformation for the last 3 years, who has been appointed Ipsen's General Manager for Belgium and Luxembourg. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen contacts Investors Khalid Deojee | + 33 6 66 01 95 26 | Media Sally Bain | +1 8573200517 | Anne Liontas | + 33 7 67 34 72 96 | Disclaimers and/or Forward-Looking StatementsThe forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen PR_EVP Strategy and Transformation_06052025
